Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

234
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
234
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

990
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
990
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

157
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncertainty-aware MAR planning with spatially explicit data-driven weighting.

The Science of the total environment·2026
Same author

Typographic self-portrait generation in an interactive museum installation.

Scientific reports·2026
Same author

Exploring student perceptions of integrating mixed reality with cadaveric teaching in undergraduate neuroanatomy education: A qualitative study.

Anatomical sciences education·2026
Same author

Vale do Côa rock art as linked open data: Application profile, schemas, and data.

Open research Europe·2026
Same author

Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages.

Journal of medical genetics·2026
Same author

Clinical and procedural outcomes of very high-power short-duration vs. standard power ablation for pulmonary vein isolation.

Frontiers in cardiovascular medicine·2026

Related Experiment Video

Updated: Dec 31, 2025

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.4K

[Severe Thrombocitopenia Induced by Fenofibrate].

Ana Clara1, Tiago Martins1, Alexandra Martins1

  • 1Serviço de Medicina Interna. Centro Hospitalar Universitário do Algarve. Faro. Portugal.

Acta Medica Portuguesa
|January 14, 2020
PubMed
Summary
This summary is machine-generated.

This case report details a rare instance of immune-mediated thrombocytopenia (low platelet count) caused by fenofibrate. Prompt drug withdrawal and corticosteroid treatment led to a favorable outcome.

Keywords:
Fenofibrate/adverse effectsPurpura, Thrombocytopenic, Idiopathic/chemically induced

More Related Videos

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

357
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K

Related Experiment Videos

Last Updated: Dec 31, 2025

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

18.4K
Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

357
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K

Area of Science:

  • Clinical Medicine
  • Pharmacology
  • Hematology

Background:

  • Drug-induced thrombocytopenia (DIT) is a significant clinical concern.
  • Differentiating non-immune from immune-mediated DIT is crucial due to potential severity.
  • Immune-mediated DIT can be life-threatening.

Observation:

  • A rare case of a 79-year-old male patient presented with purpuric rash and gingival hemorrhage.
  • Symptoms emerged on the sixth day of fenofibrate treatment.
  • Fenofibrate is rarely associated with thrombocytopenia by manufacturers.

Findings:

  • The patient experienced immune-mediated thrombocytopenia linked to fenofibrate.
  • This represents the second reported case of fenofibrate-induced immune thrombocytopenia.
  • Recovery was achieved through fenofibrate discontinuation and corticosteroid therapy.

Implications:

  • Highlights the potential for fenofibrate to cause immune-mediated thrombocytopenia.
  • Emphasizes the importance of considering drug-induced causes in thrombocytopenia diagnosis.
  • Reinforces the need for vigilant monitoring of patients on fenofibrate therapy.